Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Asahi Intecc Co ( (JP:7747) ) has issued an update.
Asahi Intecc reported net sales of 108.37 billion yen for the first nine months of the fiscal year ending June 2026, an 18.0% year-on-year increase, driven by strong demand across its Medical and Device divisions. The Medical Division posted robust growth in cardiovascular products such as PCI guidewires and penetration catheters in all regions, and in non-cardiovascular segments including peripheral and abdominal applications, particularly in overseas markets.
The Device Division also expanded, with higher sales in both medical and industrial components, aided by the consolidation of Nitta Mold as a subsidiary. Growth was supported by increased transactions in cardiovascular inspection catheter components for the U.S., cardiovascular ultrasound catheter components for Asian markets, and overseas leisure-related industrial components, while yen depreciation added about 3.1 billion yen to reported sales.
The most recent analyst rating on (JP:7747) stock is a Buy with a Yen4200.00 price target. To see the full list of analyst forecasts on Asahi Intecc Co stock, see the JP:7747 Stock Forecast page.
More about Asahi Intecc Co
Asahi Intecc Co. is a Japanese medical technology manufacturer listed on the Prime Market of the Tokyo Stock Exchange and the Premier Market of the Nagoya Stock Exchange. The company focuses on medical devices for cardiovascular and non-cardiovascular procedures, as well as medical and industrial components, serving global markets including the U.S., Europe and Asia.
Average Trading Volume: 1,343,477
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen879B
For a thorough assessment of 7747 stock, go to TipRanks’ Stock Analysis page.